Introduction
It is well-known that administration of antiepileptic drugs (AEDs) may disturb thyroid function in adults. 1 However, there are limited and conflicting data about the influence of AEDs on thyroid function in children. [2] [3] [4] [5] Valproate, carbamazepine and phenobarbital are effective and widely used antiepileptic drugs for the treatment of many types of epilepsy in children. 6 Levetiracetam and oxcarbazepine are newer
AEDs, that are increasingly used as monotherapy as well as add-on therapy in children. The effect of valproate on serum thyroid hormone concentrations has been controversial. Elevated levels of thyroidstimulating hormone (TSH) have been demonstrated in some studies, [2] [3] [4] [5] [7] [8] [9] but not in others. [10] [11] [12] [13] Carbamazepine typically causes reduced levels of free thyroxine (fT4), but has variable effects on levels of TSH. 3, 8, 11, 12, [14] [15] [16] Oxcarbazepine, a 10-keto analog of carbamazepine, was developed to attempt to reduce the side effects that have been observed with administration of carbamazepine. A few studies focused on its effects on thyroid function showed similar, but milder effects when compared to carbamazepine. 3, 4, 11, 17 There have been few studies investigating the effect of phenobarbital on thyroid function, which appears similar to those of carbamazepine and oxcarbazepine, although of smaller magnitude. 2, 8, 12, 16, 18 Levetiracetam is effective for both focal and generalized epilepsy. However very limited data exist on thyroid function in children treated with levetiracetam.
Thyroid hormone abnormalities associated with antiepileptic medications result in subclinical hypothyroidism which is defined as a mild elevation of TSH levels (5-25 mIU/l) in the presence of normal thyroid hormone concentrations. 8, 19 Subclinical hypothyroidism appears to be a benign and remitting disease with a low risk of evolution toward overt hypothyroidism and no effects on neuropsychological functions. 20 However its association with oxcarbazepine treatment may lead overt hypothyroidism. 21 Although the need for treatment of subclinical hypothyroidism remains controversial, 22 replacement therapy is not justified in children with a TSH concentration between 5 and 10 mIU/l, no goiter, and negative antithyroid antibodies. 20 The results of the few studies investigating the effects of carbamazepine and valproate on thyroid function in children with epilepsy have been controversial. [3] [4] [5] 14, 23 Moreover limited data are available for the effects of phenobarbital, oxcarbazepine and levetiracetam on thyroid function in children. Therefore, we aimed to investigate the alterations in serum fT4 and TSH levels and the frequency of subclinical hypothyroidism in children with new onset epilepsy during a 12-month period of treatment with phenobarbital, valproate, carbamazepine, oxcarbazepin and levetiracetam monotherapy.
Methods

Patients
Hospital charts of children ages 3 months to 18 years who admitted to pediatric neurology out-patient clinic at Dr. Behçet Uz Children's hospital between 1 July 2011 and 1 May 2013 were retrospectively reviewed. Children who were diagnosed with new onset idiopathic partial and generalized epilepsy, who received phenobarbital, valproate, carbamazepine, oxcarbazepine, and levetiracetam monotherapy and who were seizure free for at least 12 months were identified. All children were developmentally normal. Children those with progressive neurologic, thyroid or other metabolic diseases; those with refractory seizures; who had received any drug within the past 6 months that could affect thyroid function; those with a family history of hypothyroidism or endocrine dysfunction; or those with evidence of persistent nonadherence to medication therapy were excluded from the study. Since excess body weight can influence thyroid function, subjects were excluded in the study if the body mass index was !95th percentile for age and gender. Institutional Ethical Commitee approved the study.
During the study period, each patient was assessed and followed up by the same child neurologist according to a standard protocol that required the systematic control of fT4 and TSH levels before the beginning of AED treatment and at the first, sixth and twelfth months of therapy. Blood samples were taken between 8 AM and 10 AM after an overnight fast and measurement of fT4 and TSH levels were performed on the same day. All hormonal analyses were performed using commercial enzymatic methods at baseline or during the study period (Roche Diagnostics, Mannheim, Germany).
Detailed information including demographic characteristics, seizure type, seizure etiology, epileptic syndrome, age at onset, selected AED, and duration of AED therapy were collected. New onset epilepsy was defined as two or more unprovoked seizures. Seizure types, etiology and epilepsy syndromes were classified according to the recommendations of the International League Against Epilepsy. 24 The electroencephalography findings of all patients were interpreted by the same physician and categorized as normal, and abnormal with epileptic activity. Antiepileptic drugs were selected by the physician on the basis of the type of epilepsy and the physician's experience. Valproate was used primarily for patients with primary generalized seizures who are older than two years of age; phenobarbital was used primarily in children younger than two years of age; and carbamazepine, oxcarbazepine and levetiracetam were chosen primarily for patients with partial seizures with or without generalizations. Dosage of AEDs, seizure control, and serum levels of valproate, carbamazepine and phenobarbital were recorded at each visit. All AEDs were prescribed at the recommended dosages, and all were administered in two daily doses. The doses of AEDs were adjusted according to the clinical response and tolerability during follow-up.
Subclinical hypothyroidism was classified according to the grading system defined by Staub et al. 25 grade I, TSH greater than the upper limit of our laboratory (4.99 mIU/ml in this study) and <6 mIU/ml; grade II, TSH between 6 and 12 mIU/ml; and grade III, TSH >12 mIU/ml. Patients with grade III subclinical hypothyroidism were evaluated by a pediatric endocrinologist, and low-dose Ltyroxine replacement therapy was initiated in one patient, and the data of this patient at 6th and 12th months were not included into the analysis. Serum fT4 concentration has been considered low when it was lower than 1.0 ng/ml, which was the lower limit of our laboratory's normal reference ranges.
Statistical analysis
Values are expressed as mean AE standard deviation (SD), and analyzed using SPSS for Windows software package, version 20.0 (SPSS, Chicago, IL). Frequencies and means were calculated by descriptive analysis. For categorical variables, x 2 was used for comparing independent group differences, and Mc Nemar x 2 test for comparing related group differences. The differences in the mean serum concentrations of the thyroid hormones between the five patient groups were analyzed by the Kruskal-Wallis test. The data of the patients at different times of the study (at baseline and at the 1st, 6th, and 12th months) were evaluated by the Friedman test, with a Bonferroni post hoc test. p Values less than 0.05 were considered statistically significant.
Results
A total of 223 children consisting of 103 (46.2%) females and 120 (53.8%) males were enrolled in the study. The clinical characteristics of the children participating in the study are shown in Table 1 .
Of the 223 children, 33 (14.8%) were receiving phenobarbital, 129 (57.8%) were receiving valproate, 36 (16.1%) were receiving carbamazepine, 14 (6.3%) were receiving oxcarbazepine, and 11 (4.9%) were receiving levetiracetam monotherapy. All patients receiving phenobarbital, valproate, and carbamazepine had drug concentrations at a therapeutic level.
Serum fT4 and TSH concentrations at baseline and at the first, sixth and twelfth months of AEDs treatment are shown in Tables 2  and 3 , respectively. There was no significant difference in the average fT4 and TSH concentrations between the AED groups before the initiation of therapy. At first month of therapy, however, serum fT4 levels were found significantly decreased in carbamazepine and oxcarbamazepine groups when compared with other groups. At sixth month of therapy, a significantly lower serum FT4 levels were found in phenobarbital, carbamazepine and oxcarbamazepine groups when compared with levetiracetam and valproate groups. At twelfth month of therapy, serum fT4 levels were found significantly lower only in carbamazepine group when compared with phenobarbital, valproate and levetiracetam groups. When we analyzed the serum TSH levels between groups, significantly higher levels were found in valproate group when compared with phenobarbital, carbamazepine and levetiracetam groups at the first month; in valproate group when compared with levetiracetam group at the sixth month; and in valproate, oxcarbazepine and phenobarbital groups when compared with levetiracetam group, and in valproate group when compared with carbamazepine group at the twelfth months.
Overall, serum fT4 levels tended to decrease at the first month of therapy and this reduction persisted throughout 12-month period. In patients treated with phenobarbital, serum fT4 levels were found significantly decreased at first and sixth months of treatment, however it was not significantly different at twelfth Table 1 Characteristics of the patients treated with first-line antiepileptic drug monotherapy.
Characteristics
Total n = 223(%) Phenobarbital n = 33 (15%) Pairwise comparisons showed no significant difference between fT4 concentrations at month 1 and 6, 1 and 12, and 6 and 12 in each drug group (p > 0.05 for each analysis). Significant differences between fT4 concentrations at month 1 and 6, 1 and 12, and 6 and 12 in each drug group (p value). month when compared with baseline levels. The reduction in serum fT4 levels was significant at first, sixth and twelfth months in patients treated with valproate and carbamazepine when compared with baseline levels. In patients treated with oxcarbazepine, serum fT4 levels were found decreased significantly at first month and insignificantly at sixth and twelfth months. Serum fT4 levels in patients treated with levetiracetam were not significantly different at any measurement when compared with baseline levels (Table 2) . Except for the change between values at sixth and twelfth months in phenobarbital group, no significant change of fT4 levels were found in any drug groups throughout the study period after the beginning of therapy (Fig. 1) . At baseline 1 (3.0%) patient in phenobarbital group, 5 (3.9%) patients in valproate group, 3 (8.3%) patients in carbamazepine group, 1 (9.1%) patient in levetiracetam group and no patient in oxcarbazepine group had serum fT4 levels below the reference range. The frequency of low serum fT4 levels was found significantly increased at first and twelfth months and nonsignificantly increased at sixth month of therapy in patients treated with valproate. The frequency of low serum FT4 levels increased significantly at first, sixth and twelfth months in patients treated carbamazepine when compared baseline rate. It was significantly higher at first, and nonsignificantly higher at sixth and twelfth months of therapy in patients treated with phenobarbital and oxcarbazepine. The frequency of low serum fT4 levels was not significantly higher at any time in patients treated with levetiracetam when compared with baseline rates (Table 4) . Overall, serum TSH levels tended to increase at first month of therapy and these increased levels persisted throughout the study period. Serum TSH levels increased significantly at first, sixth and twelfth months of therapy in patients receiving valproate and phenobarbital. In children receiving carbamazepine, the increase in serum TSH levels was significant at first and sixth months, but not significant at twelfth month of therapy. Serum TSH levels were not significantly different at any measurements when compared with baseline levels in patients treated with oxcarbazepine and levetiracetam (Table 3) . After the first month of therapy, no significant change of TSH levels were seen in any drug groups (Fig. 1) .
At baseline, 10 (7.8%) patients in valproate group, 1 (2.8%) patient in carbamazepine group, 1 (7.1%) patient in oxcarbazepine group and no patient in oxcarbazepine and phenobarbital groups had serum TSH levels above the reference range of laboratory. The frequency of high serum TSH levels increased significantly at first, sixth and twelfth months in patients treated with valproate. It increased significantly at first and sixth months, and nonsignificantly at twelfth month in patients treated with carbamazepine. However no significant difference in the frequency of high serum TSH values in patients treated with phenobarbital, oxcarbazapine and levetiracetam was detected at the first, sixth and twelfth months when compared with baseline rates (Table 5 ).
Discussion
Antiepileptic drugs affect thyroid hormone levels through several mechanisms. Many of them increase hepatic microsomal enzyme systems, thus accelerating clearance of thyroid hormone, others interfere with the hypothalamic-pituitary axis. 26, 27 This study investigated the effects of widely used AEDs that included phenobarbital, valproate, carbamazepine, oxcarbazepine and Fig. 1 . The changes in serum fT4 and TSH concentrations in children receiving various antiepileptic drug monotherapy during the 12-month study period. (A) Serum fT4 concentrations decreased significantly in children receiving phenobarbital, valproate, carbamazepine, and oxcarbazepine, and nonsignificantly in children receiving levetiracetam at the first month of therapy. This low level persisted throughout the 12-month study period in patients receiving valproate, carbamazepine and oxcarbazepine. However fT4 concentrations returned to baseline levels in patients receiving phenobarbital at twelfth month. The changes were not significant at any measurements in patients receiving levetiracetam. (B) Serum TSH concentrations increased significantly in children receiving valproate and carbamazepine, and nonsignificantly in children receiving phenobarbital, oxcarbazepine and levetiracetam at the first month of therapy. This high level persisted throughout the 12-month study period only in patients receiving valproate. Serum TSH levels increased progresively in patients receiving phenobarbital and became significant at sixth and twelfth months. In patients receiving carbamazepine the increase was significant at first and sixth months, however it was nonsignificant at twelfth months. The changes were not significant at any measurements in patients receiving oxcarbazepine and levetiracetam. Table 4 Frequency of low fT4 at various times for groups divided according to antiepileptic drugs being used. The present study showed a significant increase in the TSH concentrations, and a significant reduction in the fT4 concentrations in patients treated with valproate; and these changes persisted throughout the 12-month study period. Similarly, both significantly decreased fT4 levels and significantly increased TSH levels were previously reported in patients during valproate therapy. 3, 7, 8, 23, 28 In a study of adolescent girls with epilepsy, valproate receiving group showed higher levels of TSH and lower levels of fT4 than did the untreated group, although still within normal range. 10 In other studies, however, fT4 levels were found to be unchanged while TSH levels increased in patients using valproate. 3, 4, 9, 11 On the contrary, some other studies have demonstrated that both fT4 and TSH concentrations were unaffected in patients treated with valproate 1, 11, 13, 14, 16 Similar with our results, the frequency of subclinical hypothyroidism was reported at a rate of 25.2% in patients treated with valproate, and it was found higher in patients with a duration of treatment between 6 and 24 months than those receiving valproate for less than 6 months or for more than 2 years. 7 Another study has shown that prolonged duration of valproate therapy for more than 24 months was associated with higher risk of subclinical hypothyroidism. 9 We did not observe an increase in frequency of subclinical hypothyroidism after the first month of therapy, instead it remained relatively stable during the rest of the study period. Several previous studies have shown that the reduced fT4 and increased TSH concentrations returned to normal values after the withdrawal of valproate. 2, 3, 23 Thus, the changes induced by long term administration of valproate appear to be transient and reversible.
Carbamazepine is known to accelerate the metabolism of thyroid hormones by inducing of the hepatic P450 enzyme system which causes increased metabolism of thyroid hormones, and by interfering with thyroid hormone competitive binding to thyroidbinding globulin. 3 In the present study, children received carbamazepine showed a significant reduction in fT4 concentrations throughout the 12-month period and significantly increased TSH concentrations at the first and sixth months of therapy.
Similarly, a previous study showed a significant reduction in the levels of fT4 and a significant increase in the levels of TSH in children treated with carbamazepine. 2 In our study, although serum TSH concentration was still higher than the baseline values in children receiving carbamazepine, the difference was not significant anymore at the twelfth month of therapy. This finding was in line with a previous study which has shown that TSH levels increased during the first 4-20 days of treatment, and then declined rapidly to normal levels. 29 The changes induced by carbamazepine appear to return to normal values after the withdrawal of medication. 2, 3, 30 Subclinical hypothyroidism was previously reported in 8.2% of 61 children receiving carbamazepine. 8 We found a relatively higher frequency of subclinical hypothyroidism in patients receiving carbamazepine (19.% at the first month, 27.8% at the sixth month and 13.9% at the twelfth month). Oxcarbazepine, despite its close structural resemblance, does not induce enzyme activity to a similar extend as does carbamazepine. 17 Indeed, low serum thyroid hormone levels induced by carbamazepine have been shown to normalize after replacement of carbamazepine with oxcarbazepine in adults.
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Several studies have demonstrated that serum fT4 levels were significantly reduced in patients receiving oxcarbazepine, whereas TSH concentrations remained unchanged in children. [2] [3] [4] In consistent with these reports, in the present study, serum fT4 concentrations decreased significantly at the first month of therapy, and these low levels persisted throughout the 12-month study period, whereas the increase in TSH concentration was insignificant. Similarly, a previous study revealed reduced fT4 levels occurring in the early stages of oxcarbazepine therapy in children. 4 Moreover, subclinical hypothyroidism associated with oxcarbazepine treatment may lead overt hypothyroidism. 21 By contrast, another study has reported short-term oxcarbazepine treatment in adults had no deleterious effect on thyroid hormone status. 31 In addition, the reduced fT4 concentrations were found to return to normal values after the withdrawal of oxcarbazepine. 3 Thus, it appears that the effect of oxcarbazepine on thyroid function is short term, transient and less significant than the effect of carbamazepine. Children with epilepsy during chronic treatment with phenobarbital were found to have significantly reduced fT4 levels but Table 5 Frequency of high TSH at various times for groups divided according to antiepileptic drugs being used. unchanged TSH concentrations when compared with controls. 2, 8, 16 By contrast, another study has demonstrated no significant differences in serum fT4 and TSH levels between the patients receiving phenobarbital and the control group. 18 Phenobarbital was found to lower T3 and T4 levels only when it has been used for longer than six years. 16 In our series, serum fT4 concentrations in patients receiving phenobarbital were found significantly reduced at the first and sixth months, however this reduction did not persist at twelfth month. By contrast serum TSH levels showed a significant and progressive increase throughout the 12-month treatment. However the changes on THS concentrations were less marked than those in patients treated with valproate. A previous study has shown that the increased TSH concentrations returned to normal values after the withdrawal of phenobarbital. 2 Thus, the effects of phenobarbital on thyroid function appear reversible.
Levetiracetam is considered to have fewer side effects than older AEDs. However, data on the effects of levetiracetam on thyroid function are scant. In a recent study, thyroid function were found unaffected in five children receiving levetiracetam during a 9-month period. 18 In consistent with this report, fT4 and TSH levels were found unchanged in our patients receiving levetiracetam during the 12-month period of observation. In the limited number of studies, the prevalence of subclinical hypothyroidism in children was reported to be slightly lower than 2%. 32 In studies investigating the effects of AEDs on thyroid function, the frequency of subclinical hypothyroidism in healthy controlled children have been found between 0% and 7.7%. 2, [7] [8] [9] In our series, overall 12 (5.4%) patients had serum TSH levels above the reference range before the beginning of antiepileptic therapy. The exact pathogenic mechanisms underlying the association between epilepsy and disturbed thyroid function have not been fully elucidated. The relatively high frequency of subclinical hypothyroidism in epileptic children before the initiation of antiepileptic medication may suggest that epilepsy itself has a role on thyroid function, as some researchers claim that epilepsy plays a pathogenic role in the occurrence of endocrine disorders. 33, 34 Obviously this controversial issue needs to be clarified with further studies.
Limitations
One of the limitations of our study was that we were not able to form a control group because of ethical reasons. This limitation may be omitted with using baseline values as controls. As a retrospective study, we were constrained by the information available on the medical records. However, a standard protocol that required the systematic control of fT4 and TSH levels before the beginning of antiepileptic treatment and at the first, sixth and twelfth months of AED treatment lessened the effect of this limitation. Moreover all patients in the study group have been assessed and followed-up by a single child neurologist (U.Y.) who also recorded all measurements on patients' charts, which further lessened the effect of retrospective design of the study. Another limitation of the study was the lack of adjustment of fT4 and TSH values for body mass index. It has previously been shown that serum TSH were positively and FT4 was negatively associated with BMI in healthy euthyroid children. 35 We have excluded patients if the body mass index was !95th percentile for age and gender at baseline, however we did not adjust fT4 and TSH measurements for body mass index in the analysis due to the lack of data for height of the patients at first, sixth, and twelfth months of study period. The small sample size of oxcarbazepine and levetiracetam groups was the other limitation of the study. While valproate, carbamazepine and phenobarbital are widely used first-line AEDs in daily clinical practice, levetiracetam and oxcarbazepine are recently began to be used in the initial treatment of childhood epilepsy. For this reason, numbers of children receiving these AEDs were small, and findings presented in this study may be regarded as preliminary data for the effects of levetiracetam and oxcarbazapine on thyroid function in children. Further studies with larger samples are needed to clarify the effects of these AEDs on thyroid function.
Conclusion
In conclusion, all AEDs except levetiracetam studied had deleterious effects on thyroid function with varying degrees in children during the period of 12-month therapy. The effects on thyroid function induced by valproate and carbamazepine appear to be more marked than those induced by phenobarbital and oxcarbazepine. Therefore, evaluation of thyroid function should be considered in children receiving valproate and carbamazepine monotherapy.
Conflict of interest statement
None.
